Kwo Elizabeth

SEC source: 0001193125-26-399696 · ownership.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,116

F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.2200 to $24.3200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

SEC source: 0001193125-26-388308 · ownership.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,126

F1 · shares: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

F1 · price: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

SEC source: 0000950170-25-113623 · ownership.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,909

F1 · shares: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

F1 · price: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

SEC source: 0001437749-24-027547 · rdgdoc.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effectiveness of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.

SEC source: 0001209191-23-035521 · doc4.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,201

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2024 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · price: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2024 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

SEC source: 0001209191-22-037122 · doc4.xml · derivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,340

Underlying: Common Stock · 55,340 shares

Expires 2029-06-14

F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan.

F2 · derivative.exercise_date: The stock options will vest on a quarterly basis over the one year following the date of grant, with the first vesting on the date of grant.

SEC source: 0001209191-22-019067 · doc4.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,201

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.53 to $0.5313, with a weighted average price per share of $0.5310. The reporting person undertakes to provide to Asensus Surgical, Inc., any security holder of Asensus Surgical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: Includes 54,201 shares underlying restricted stock units that were granted on July 22, 2021, and will vest one-third each on the first, second and third anniversaries of the date of grant as long as the reporting person continues to provide service to Asensus Surgical, Inc.

SEC source: 0001209191-21-065718 · doc4.xml · derivative · entry 3

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2031-06-23

F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

SEC source: 0001209191-21-065718 · doc4.xml · derivative · entry 2

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires 2030-08-17

F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

SEC source: 0001209191-21-065718 · doc4.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.

F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.

SEC source: 0001209191-21-048246 · doc4.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units granted on July 22, 2021. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. The forfeiture restrictions will lapse on one-third of the award on the first, second and third anniversaries of the date of grant, subject to continued service on the Board of Directors.

F1 · balance_after: Represents restricted stock units granted on July 22, 2021. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. The forfeiture restrictions will lapse on one-third of the award on the first, second and third anniversaries of the date of grant, subject to continued service on the Board of Directors.

SEC source: 0001209191-21-043557 · doc4.xml · derivative · entry 2

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2031-06-23

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant.

SEC source: 0001209191-21-043557 · doc4.xml · nonDerivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.

SEC source: 0001209191-20-047749 · doc4.xml · derivative · entry 1

Kwo Elizabeth · CIK 0001820001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2030-08-17

F1 · derivative.exercise_date: One-third of the shares subject to the option will vest on August 18, 2021 and the balance of the shares will vest in a series of 24 equal monthly installments thereafter.